Reference Detail

Ref Type

Abstract

PMID

Authors

C. Lebbe G.V. Long C. Robert O. Hamid V.G. Atkinson A.N. Shoushtari A. Daud O.E. Bechter D. Schadendorf R.J. Sullivan R. Dummer J.J. Grob N. Lewis L. Fan S. Basu G. Caponigro V.G. Cooke A. Lau R. Amaria

Title

Phase II study of multiple LXH254 drug combinations in patients (pts) with unresectable/metastatic, BRAF V600- or NRAS-mutant melanoma

Journal	Vol	Issue	Date	Pages	Journal Short Title
Annals of Oncology	33	SUPPLEMENT 7	September 01, 2022

URL

https://www.annalsofoncology.org/article/S0923-7534(22)03916-3/fulltext

Abstract Text

Background The mitogen-activated protein kinase pathway is often dysregulated in melanoma. LXH254, an oral RAF inhibitor, inhibits BRAF and CRAF. We explore LXH254 combined with LTT462 (ERK1/2 inhibitor), trametinib (MEK1/2 inhibitor), or ribociclib (CDK4/6 inhibitor) in previously treated, BRAF V600 or NRAS-mutant melanoma. Methods Phase II, open-label study (NCT04417621) with a selection part followed by expansion. In selection, pts with melanoma (BRAF V600 and NRAS mutations separately allocated) were randomized to receive LXH254 (400 mg twice daily [BID]) + LTT462 (200 mg once daily [QD]; L+L), trametinib (0.5 mg QD; L+T), or ribociclib (400 mg QD; L+R). Based on Phase I expansion data, the L+T regimen was changed to LXH254 200 mg BID + trametinib 1 mg QD (L+T1). Pts had previously received ≥1 anti–PD-(L)1 inhibitor; pts with BRAF V600-mutant disease had prior treatment (Tx) with a BRAF inhibitor ± a MEK inhibitor as the most recent Tx line. The primary objective was to evaluate the efficacy of LXH254 combinations based on overall response rates. Key secondary objectives were safety and tolerability. Results As of May 2, 2022, 48 BRAF V600-mutant and 86 NRAS-mutant pts with advanced melanoma were enrolled; 77% had received ≥2 prior Txs. Table shows responses. Overall, 96% of pts had Tx-related adverse events (TRAEs) of any grade, most commonly rash (35%; L+L: 36%, L+T: 36%, L+T1: 40%, L+R: 23%), acneiform dermatitis (28%; L+L: 29%, L+T: 41%, L+T1: 27%, L+R: 14%), nausea (25%; L+L: 30%, L+T: 23%, L+T1: 10%, L+R: 27%), pruritus (24%; L+L: 25%, L+T: 21%, L+T1: 23%, L+R: 14%), and fatigue (21%; L+L: 17%, L+T: 14%, L+T1: 27%, L+R: 32%). Grade 3/4 TRAEs occurred in 46% of pts: rash (7%) was most common. Conclusion: These combinations exhibited tolerable safety profiles; most common toxicities were cutaneous. LXH254 in combination with LTT462 or trametinib shows promising efficacy in NRAS-mutant, immuno-resistant melanoma.

Filtering

Case insensitive filtering will display rows if any text in any cell matches the filter term
Use simple literal full or partial string matches
Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
Click on any column header arrows to sort by that column
Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile	Treatment Approach

Gene Name	Source	Synonyms	Protein Domains	Gene Description	Gene Role

Therapy Name	Drugs	Efficacy Evidence	Clinical Trials

Drug Name	Trade Name	Synonyms	Drug Classes	Drug Description

Gene	Variant	Impact	Protein Effect	Variant Description	Associated with drug Resistance

Molecular Profile	Indication/Tumor Type	Response Type	Therapy Name	Approval Status	Evidence Type	Efficacy Evidence	References
NRAS mutant	melanoma	predicted - sensitive	LTT462 + LXH 254	Phase II	Actionable	In a Phase II trial, combination treatment with LXH 254 and LTT462 demonstrated tolerable safety in patients with NRAS-mutant melanoma, and led to a disease control rate of 62% (18/29), with a confirmed partial response in 6 patients and stable disease in 12 patients (Ann Oncol (2022) 33 (suppl_7): S197-S224; NCT04417621).	detail...